Navigation Links
FDA Approves Boston Scientific's Apex(TM) PTCA Dilatation Catheter
Date:11/10/2008

New design provides more options for treating patients with complex lesions

NATICK, Mass., Nov. 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration to market its Apex(TM) PTCA(1) Dilatation Catheter. The Apex Catheter is a high-performance pre-dilatation balloon catheter developed specifically to address physicians' needs in treating the most challenging atherosclerotic lesions. It is available for distribution in both Monorail(R) and Over-The-Wire (OTW) catheter platforms.

The Apex Catheter represents the next generation of dilatation catheter technology, utilizing a new Bi-Segment(TM) inner shaft for improved pushability and flexibility. Additionally, it has a redesigned tip with the same low profile as the Maverick(R) PTCA Dilatation Catheter for excellent turning and wire tracking.

It is available in a wide array of balloon diameters from 1.5mm up to 5.0mm, with balloon lengths ranging from 8mm up to 40mm (for select diameters). Both the Apex Monorail and OTW catheters are available in two different 1.5mm designs -- "Apex Push Catheter" and "Apex Flex Catheter." The Apex Push Catheter is designed to enhance pushability for tight lesions, while the Apex Flex Catheter is designed to enhance trackability for tortuous arteries. The two 1.5mm Apex Catheter designs enable physicians to select the appropriate catheter based on the clinical situation.

"A much greater number of 'complex' lesions could be more readily crossed and dilated if more advanced, next-generation, catheter technology were available," said James Hermiller, M.D., Director of the Interventional Fellowship at St. Vincent Heart Center of Indiana
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... From cell phones to cars and flashlights, ... Scientists and technology companies constantly are seeking ways ... the first time using a water-based solution, researchers ... long-lasting and more efficient nuclear battery that could ... reliable energy source in automobiles and also in ...
(Date:9/16/2014)... CHAPEL HILL, N.C. , Sept. 16, 2014 /PRNewswire/ ... its experimental heart failure compound has been shown to ... The preclinical results demonstrate an alternative to intravenous infusions ... with HNO prodrugs. The data were presented yesterday at ... Annual Scientific Meeting in Las Vegas ...
(Date:9/16/2014)... , Sept. 16, 2014  The Council ... entrepreneurial support organization in the country, today released ... Report . It showed that ... North Carolina startups in the technology, ... more global investment from a variety of sources. Significant ...
(Date:9/16/2014)... Convoy Therapeutics, Inc., a specialty ... to treat patients directly at the site of ... Technology Platform announced today that John Muraski, Ph.D., ... the White Hat Life Science Investor Conferenceā„¢ on ... In addition, interested individuals can meet Convoy ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... To highlight its 20 years of experience as ... ( www.microtestlabs.com ) is offering free microbial identification ... tests, to eligible attendees visiting the Microtest exhibit, #828, ... highlight Microtest,s wide range of laboratory testing and validation ...
... RGEN ) announced today that the Company ... will present at the BIO CEO and Investor Conference ... at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, ... available via Repligen,s website at www.repligen.com and ...
... Secretropin(R) , the first clinically proven natural stimulator of ... as a more desirable "first step" approach to pursuing ... Secretropin(R) is only available through ... to increase the body,s own production and release of ...
Cached Biology Technology:Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees 2Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST 2Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum 2
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... make us sick can take up residence in and ... or other troublesome symptom, according to new research at ... , On average, healthy individuals carry about five types ... in BioMed Central Biology . The study is ... viruses in healthy people. , The research was ...
(Date:9/16/2014)... chunk of rock hit the Yukatan peninsula near the site ... 100 teratons of TNT. It left a crater more than ... and volcanism are widely accepted to have wiped out the ... But what happened to the plants on which the dinosaurs ... University of Arizona reveals that the meteorite impact that spelled ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... - Primary Energy Recycling Corporation (TSX: PRI), (the "Company") a clean energy company ... announced its financial and operational results for the first quarter ended March ... Highlights for the ... 4.3% for the three months ended March 31, 2010, ...
... Spain and the UK have identified the final piece in ... Published today by PNAS, the breakthrough discovery by the Consejo ... of East Anglia (UEA) has implications for agribusiness, the environment ... deposit which accumulates in the seeds, beans and tubers of ...
... cystic fibrosis can be caused by genetic "nonsense mutations" ... Bedwell, Ph.D., a professor in the University of Alabama ... now closer to producing drugs that will fix this ... Bedwell is a renowned researcher on the select group ...
Cached Biology News:Primary Energy Reports Improved First Quarter Results 2Primary Energy Reports Improved First Quarter Results 3Primary Energy Reports Improved First Quarter Results 4Primary Energy Reports Improved First Quarter Results 5Scientists discover final piece in phytate jigsaw 2Drug may treat cystic fibrosis, other diseases caused by 'nonsense mutations,' UAB researcher says 2